3.80
-0.1588(-4.01%)
Currency In USD
| Previous Close | 3.96 |
| Open | 3.75 |
| Day High | 3.85 |
| Day Low | 3.65 |
| 52-Week High | 12.22 |
| 52-Week Low | 3.36 |
| Volume | 1,113 |
| Average Volume | 2,278 |
| Market Cap | 140.17M |
| PE | -1.78 |
| EPS | -2.14 |
| Moving Average 50 Days | 3.76 |
| Moving Average 200 Days | 4.63 |
| Change | -0.16 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $193.45 as of July 31, 2025 at a share price of $3.801. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 2 years ago, it would be worth $605.29 as of July 31, 2025 at a share price of $3.801.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
GlobeNewswire Inc.
Jun 22, 2025 8:00 PM GMT
MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor accumulation and attractive biodistribution shown in
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
GlobeNewswire Inc.
Jun 11, 2025 8:00 PM GMT
Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosingData s
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
GlobeNewswire Inc.
Jun 10, 2025 5:00 AM GMT
Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR